Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10132028 | 0.94 | ALDH1A1 (0.40) | RAB9ANPC1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL16280991 | 0.80 | DNM1 (0.40) | RAB9AKMT2AALDH1A1POLBDNM1 | |
| SCHEMBL10132042 | 0.76 | MAOA (0.40) | KMT2AALDH1A1SMN1; SMN2POLBRECQL | |
| SCHEMBL10132083 | 0.73 | MAOA (0.47) | KMT2AALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL16280974 | 0.73 | DNM1 (0.42) | KMT2AALDH1A1POLBDNM1MEN1 | |
| SCHEMBL24754796 | 0.72 | DNM1 (0.44) | RAB9AKMT2AALDH1A1POLBRECQL | |
| SCHEMBL10132099 | 0.72 | SMN1; SMN2 (0.53) | ALDH1A1SMN1; SMN2EPHX2 | |
| SCHEMBL10132085 | 0.71 | SMN1; SMN2 (0.65) | KMT2AALDH1A1SMN1; SMN2EPHX2MEN1 | |
| SCHEMBL10132039 | 0.71 | ALDH1A1 (0.52) | RAB9ANPC1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL13853864 | 0.71 | RAB9A (0.48) | RAB9ANPC1ALDH1A1SMN1; SMN2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101186-B2 | Peptides that block the binding of IgG to FcRn | SYNTONIX PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20070254831-A1 | PEPTIDES THAT BLOCK THE BINDING OF IgG to FcRn | BIOGEN HEMOPHILIA INC. | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254831-A1 | PEPTIDES THAT BLOCK THE BINDING OF IgG to FcRn | FCGRT, FCGR3B, FCGR1A | RAB9A 2182/4885NPC1 3424/4885KMT2A 4447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.